Regeneron Pharmaceuticals, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Regeneron is an integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. This report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The interim financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $3,145.0 million | $3,162.1 million | (0.5%) |
| Net product sales | $1,761.3 million | $1,668.0 million | +5.6% |
| Collaboration revenue | $1,266.8 million | $1,378.1 million | (8.1%) |
| Income from operations | $751.4 million | $946.7 million | (20.6%) |
| Operating margin | 23.9% | 29.9% | Down 6.0 percentage points |
| Net income | $722.0 million | $817.8 million | (11.7%) |
| Diluted EPS | $6.27 | $7.17 | (12.6%) |
| Net margin | 23.0% | 25.9% | Down 2.9 percentage points |
| Operating cash flow | $1,512.5 million | $1,367.6 million | +10.6% |
Revenue was broadly stable because higher product sales and Sanofi collaboration revenue were largely offset by the sharp decline in Roche revenue related to Ronapreve. Net income declined despite lower income taxes, primarily because operating expenses increased and equity-security losses remained significant.
Revenue and Product Performance
- EYLEA HD U.S. sales were $200.0 million in its first reported quarter. Combined U.S. EYLEA HD and EYLEA sales were $1,401.6 million, down from $1,433.8 million, as EYLEA sales declined $232.2 million while EYLEA HD partially offset the decrease.
- Libtayo global sales increased 49% to $263.9 million.
- Praluent U.S. sales increased 74% to $70.0 million, and Evkeeza U.S. sales increased 66% to $24.8 million.
- Sanofi collaboration revenue increased to $909.8 million from $798.4 million, driven by higher Dupixent-related profits. Regeneron's share of Dupixent and Kevzara collaboration profits was $804.0 million after reimbursement of $121.9 million of Sanofi development expenses.
- Bayer collaboration revenue was essentially unchanged at $356.0 million.
- Roche collaboration revenue fell to $0.5 million from $222.2 million, reflecting the substantial reduction in Ronapreve-related profit payments.
Expenses, Margins, and Unusual Items
- Research and development expense increased 13% to $1,248.4 million, with higher spending on fianlimab, linvoseltamab, other pipeline programs, personnel, and clinical manufacturing.
- Selling, general, and administrative expense increased 15% to $689.0 million, primarily due to EYLEA HD launch costs, higher headcount, international Libtayo expansion, and hematology launch preparation.
- Cost of goods sold increased to $240.4 million, partly due to start-up costs for the Rensselaer fill/finish facility.
- Cost of collaboration and contract manufacturing declined to $193.4 million, primarily due to lower Dupixent manufacturing costs from a higher-yielding process.
- The Company recorded a $15.3 million operating charge from remeasurement of Decibel acquisition-related contingent consideration.
- Other expense included $196.2 million of net unrealized losses on equity securities, partly offset by $161.5 million of interest income. The effective tax rate was a benefit of 3.0%, compared with a 4.7% tax expense rate in Q1 2023, primarily due to stock-based compensation and lower-tax foreign income.
Cash Flow, Liquidity, and Debt
- Cash, cash equivalents, and restricted cash declined $128.0 million during the quarter to $2,609.8 million.
- Marketable securities totaled $14,896.3 million, including $7,917.5 million classified as current and $6,978.8 million as noncurrent. The portfolio included $781.3 million of equity securities.
- Operating cash flow was $1,512.5 million. Investing activities used $1,687.1 million, principally because of purchases of marketable securities, capital expenditures, and Libtayo-related payments.
- Capital expenditures were $133.9 million. Management expects full-year 2024 capital expenditures of $780 million to $880 million, primarily for Tarrytown and Rensselaer facility expansion.
- Long-term debt was $1,983.3 million and finance lease liabilities were $720.0 million. Total outstanding indebtedness under senior notes and the lease financing facility was approximately $2.703 billion.
- Working capital was $15,290.6 million, and the Company had $750.0 million available under its revolving credit facility.
- The Company repurchased $298.0 million of common stock during the quarter. Of the existing $3.0 billion authorization, $1.233 billion remained available at March 31, 2024. In April 2024, the board authorized an additional $3.0 billion repurchase program.
Material Changes, Outlook, and Management Commentary
- The principal commercial transition is the launch of EYLEA HD, while U.S. EYLEA sales face lower volume and net pricing and impending biosimilar competition. U.S. EYLEA regulatory exclusivity expires after May 17, 2024.
- Management expects continued substantial investment in research and development, commercialization, and manufacturing capacity. Profitability and operating cash flow are significantly dependent on EYLEA HD, EYLEA, and Dupixent.
- Selected expected 2024 milestones include an EYLEA HD RVO Phase 3 study and supplemental filing, regulatory decisions for Dupixent and Kevzara indications, a decision on linvoseltamab with an FDA target action date of August 22, 2024, and an EU decision for odronextamab.
- FDA issued Complete Response Letters for odronextamab applications for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma because of confirmatory-trial enrollment status.
- Enrollment in a Phase 2 vidutolimod study was paused because of drug-supply issues.
- Regeneron's contingent reimbursement obligation to Sanofi for funded development expenses was approximately $2.200 billion at March 31, 2024. The Company is generally required to apply 20% of its collaboration profit share each quarter toward this obligation.
Risks, Contingencies, and Unusual Items
- The Company is exposed to significant EYLEA and EYLEA HD patent challenges, inter partes review proceedings, biosimilar litigation, and related proceedings in the United States, Europe, Canada, and Asia.
- The Department of Justice and the U.S. Attorney's Office for the District of Massachusetts have intervened in civil proceedings involving alleged False Claims Act, Anti-Kickback Statute, pricing, discounts, rebates, and patient-assistance practices. Additional investigations and private-payor lawsuits remain pending.
- Accrued legal loss contingencies were not material, but certain reasonably possible losses were not estimable.
- Revenue is concentrated among distributors: Besse Medical and McKesson represented 51% and 24%, respectively, of total gross product revenue in Q1 2024.
- Collaboration dependence is material, particularly on Sanofi for Dupixent and Kevzara and on Bayer for EYLEA and EYLEA HD outside the United States.
- Key operating risks include product reimbursement and pricing pressure, competition, regulatory approval and safety outcomes, manufacturing and fill/finish capacity, intellectual-property challenges, clinical-trial execution, cybersecurity, data privacy, foreign exchange, and potential changes in healthcare regulation.
Important Facts for Investors to Verify
- Whether EYLEA HD uptake offsets declining EYLEA volume and pricing after U.S. biosimilar competition begins.
- Progress and outcomes of EYLEA patent litigation and post-grant proceedings, including the impact on market exclusivity.
- Dupixent and Kevzara regulatory decisions, including the Dupixent COPD review and CSU development program.
- Regulatory progress for linvoseltamab, odronextamab, fianlimab, and other late-stage candidates.
- The magnitude and timing of Sanofi development-balance reimbursements and the continued economics of the Sanofi and Bayer collaborations.
- Capital spending and the operational validation of the Rensselaer fill/finish facility.
- Developments in Department of Justice investigations, False Claims Act litigation, and related payor lawsuits.
- Distributor concentration, inventory levels, marketable-security losses, and the effect of equity-market volatility on reported earnings.